-The Hindu   No one can attack India's well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) laws have been the subject of sharp criticism recently. Now, there is talk of the government invoking emergency provisions with regard to Dasatinib, a cancer drug. The decibel level may go up several notches. Let us look...

-Frontline   A Delhi High Court verdict says the State government is bound to ensure that poor and vulnerable sections of society have access to treatment for rare and chronic diseases. SEVEN-YEAR-OLD Mohammed Ahmed Khan looked on helplessly as his father, Sirajuddin, narrated the sordid tale of the loss of four of his children to Gaucher's disease, a rare genetic disease that requires lifelong, exorbitantly expensive enzyme replacement therapy. Sirajuddin, a rickshaw...

-The Telegraph New Delhi: Allegations that the government was denying services like marriage registration and property sales to people lacking Aadhaar cards today annoyed the Supreme Court, which ordered that any notification making the scheme mandatory must be withdrawn immediately. Solicitor-general Mohan Parasaran assured the court that if any such notification had indeed been issued, it would be withdrawn. Official sources told The Telegraph that no such notification had been issued and that...

A new report entitled Improving Access to Finance for Women-owned Businesses in India (2014), jointly produced by the International Finance Corporation (IFC) and Government of Japan, underlines the importance of lending to women-owned micro, small and medium enterprises (MSMEs)* in India (see the link below). It discusses the problem of accessing finance faced by women entrepreneurs despite them having stronger repayment track records vis-à-vis men (non-performing loans are 30 to...

-The Hindu Differences over intellectual Property rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...